Download P124 Cytoplasmic expression of iga1 protein is a factor of poor

156
A B S T R A C T S / E U R O P E A N U R O L O G Y S U P P L E M E N T S 13 (2014) 103—194
with MIBC with Hazard Ratio 2.39 (CI 95% 1.03–8.55) p<0.05. Other
parameters as a correct LD, number of implants, sex and age did not
show statistically significant difference. No significant differences between the two groups for: age, sex, presence of carcinoma in situ,
correct LD, positive nodes, number of implants and metastatic progression.
Conclusions: Our study has shown that Progressive MIBC do not
have a worse prognosis than Primary. Positive nodes in RC specimens seems to be an independent factor that decreases survival in
patients with MIBC. In our series, parameters such as age, sex, correct
LD, number of implants had not statistically significant differences
regarding overall survival.
P122
High visfatin expression predicts poor prognosis of upper tract
urothelial carcinoma
I-S. Lo, S-H Chen. Kaohsiung Medical University Hospital, Dept. of
Urology, Kaohsiung, Taiwan
Introduction & Objectives: Visfatin, a newly discovered adipocytokine, is a pro-inflammatory cytokine. This study aimed to evaluate
the predictive value of visfatin on prognosis of patients with upper
tract urothelial carcinoma.
Material & Methods: One-hundred and five patients (median age =
64, range = 24–84 years) were included in this study. Visfatin expression in upper tract urothelial carcinoma tissues was analyzed by immunohistochemistry. Visfatin expression was correlated with clinicopathologic variables using the χ2 test. The prognostic value of visfatin for recurrence-free and cance-specific survival was evaluated by
Kaplan-Meier estimates, and the significance of differences between
curves was evaluated by the log-rank test. Cox regression model was
also used to evaluate the hazard ratios of visfatin on survival.
Results: High visfatin expression in upper tract urothelial carcinoma
tissues was significantly correlated with tumor stage, grade and
p53 expression. High visfatin expression was associated with poor
recurrence-free and cancer-specific survival. Cox regression analysis
also revealed that visfatin is an independent predictor of recurrencefree and cancer-specific survival.
Conclusions: Our findings indicated that higher visfatin expression
is a potential biomarker to predict patient survival. Further study is
necessary to investigate the role of visfatin in the carcinogenesis of
upper tract urothelial carcinoma.
P123
Bladder tumour history, does it predict worse survival in upper
tract transitional cell carcinoma?
B. Akdoğan, B. Çıtamak, M. Altan, B. Özdemir, B. Haberal, H. Özen.
Hacettepe University, Fac. of Medicine, Dept. of Urology, Ankara, Turkey
Introduction & Objectives: To evaluate prognostic factors in upper
tract transitional cell carcinoma (UUTTCC).
Material & Methods: Since 1987, 127 patients (104 men, 23 women)
with a mean age of 61.5±1.02 years have undergone nephroureterectomy and bladder cuff removal. Patient age, sex, anaemia, bladder tumour history, bladder recurrences, tumour stage, grade and location
were evaluated as prognostic factors.
Results: Mean follow up was 57.3±4.6 months. Overall 5-years survival was 60.6%. Univariate analysis revealed anaemia, positive bladTable 1. Cox regression analysis for 5-years overall survival in UUTTCC
Parameter
Age, years
Sex
Bladder tumour history
Stage
Grade
Tumour localization
Hazard ratio
p
1.258 (0.72–2.19)
0.494 (0.22–1.07)
2.040 (1.07–3.87)
1.903 (1.034–3.504)
1.721 (1.146–2.584)
1.156 (0.610–2.19)
0.417
0.076
0.029
0.039
0.09
0.657
der tumour history, T stage, grade and tumour location in the upper
tract as significant prognostic factors (HR=). On multivariate analysis
T stage, grade and bladder tumour history were significant variables
for the 5-years overall survival (HR=1.903, 1.721 and 2.04, respectively) (Table 1).
Conclusions: Tumour stage and grade are well known prognostic factors as found in our study. Bladder tumour history is the most important prognostic parameter with highest HR in this series. Patients
with bladder tumour should regularly and strictly followed-up for an
upper tract recurrence which causes worse survival.
P124
Cytoplasmic expression of iga1 protein is a factor of poor
prognosis in urothelial bladder cancer
B. Nodin, B. Jansson, E. Nilsson, C. Welinder, K. Jirstrom, A. Gaber.
Facutly of Medicine, Dept. of Oncology and Pathology, Lund, Sweden
Introduction & Objectives: Immunoglobulin A (IgA) has previously
been found in various tumour tissue as well as in serum of epithelial cancer patients, and moreover IgA has been found to carry the
Tn-antigen (GalNac α-Ser/Thr), which upregulated has been liked to
poor prognosis. However to our knowledge, no study has previously
investigated IgA expression and prognosis. In the present study, we
examined the prognostic significance of IgA1 expression in a cohort
comprising 110 cases of uroepithelial cancers.
Material & Methods: Immunohistochemical expression of cytoplasmic IgA1 was evaluated in tissue microarrays with tumours from one
retrospective cohort of uroepithelial cancer patients (n=110). Classification regression tree analysis was applied for selection of prognostic cutoff. Kaplan-Meier analysis, log rank test and Cox regression
proportional hazards’ modeling were used to evaluate the impact of
IgA1 overall survival (OS).
Results: IgA1 expression could be evaluated in tumours from 99/110
cases. Cytoplasmic IgA1 expression correlated to more advanced Tstage (p<0.009), high grade tumours (p=0.008), male sex (p=0.003),
loss of membranous expression of ezrin (p=0.030). Moreover, IgA1
expression was associated with an impaired OS (HR=1.99, 95% CI
1.16–3.43), remaining sigificant in multivariable analysis, adjusted
for age, grade, T-stage and ezrin expression (HR=2.04, 95% CI 1.11–
3.76).
Conclusions: The results from this study demosntrate, for the first
time, that IgA1 expression is differentially expressed in urothelial bladder cancer, and that high expression is associated with
unfavourable clinicopathological characteristics and independently
predicts an impaired survival. The utility of IgA1 as a prognostic
biomarker in transurethral resection specimens merits further investigation.
P125
Epidemiology of bladder cancer in Niamey: An analysis of the
Niger cancer registry data
S. Mamoudou Garba 1 , H. Hami 2 , H. Mahamadou Zaki 1 ,
A. Soulaymani 2 , H. Nouhou 1 , A. Quyou 2 . 1 Laboratory of Pathological
Anatomy and Cytology, Faculty of Health Sciences, Dept. of Abdou
Moumouni University, Niamey, Niger; 2 Laboratory of Genetics and
Biometry, Faculty of Science, Dept. of Ibn Tofaïl University, Kenitra,
Morocco
Introduction & Objectives: Bladder cancer is the sixth most common
malignancy of the urinary tract in men and the 11th most common
cancer in women. It is also the 9th leading cause of cancer death in
men and the 14th most common cause of cancer death in women in
Western Africa, with about 2 900 new cancer cases (1 741 men and
1 159 women) and 1 894 deaths from cancer in both sexes in 2012
(GLOBOCAN 2012). The aim of this study is to estimate the occurrence of bladder cancer in Niamey, in terms of incidence and describe
its epidemiological characteristics.